QPTFF (Quest PharmaTech) LT-Debt-to-Total-Asset: 0.00 (As of Jan. 2026)


What is Quest PharmaTech LT-Debt-to-Total-Asset?

Quest PharmaTech QPTFF LT-Debt-to-Total-Asset is 0.00 as of Jan. 2026.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Quest PharmaTech's long-term debt to total assests ratio for the quarter that ended in Jan. 2026 was 0.00.

Quest PharmaTech's long-term debt to total assets ratio stayed the same from Jan. 2025 (0.00) to Jan. 2026 (0.00).

Quest PharmaTech  (OTCPK:QPTFF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Quest PharmaTech LT-Debt-to-Total-Asset Related Terms

Quest PharmaTech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Quest PharmaTech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest PharmaTech LT-Debt-to-Total-Asset Chart

Quest PharmaTech Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Quest PharmaTech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Quest PharmaTech LT-Debt-to-Total-Asset Calculation

Quest PharmaTech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (A: Jan. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Jan. 2026 )/Total Assets (A: Jan. 2026 )
=0/20.154
=

Quest PharmaTech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (Q: Jan. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2026 )/Total Assets (Q: Jan. 2026 )
=0/20.154
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Quest PharmaTech (QPTFF) has a LT-Debt-to-Total-Asset of 0.00 as of Jan. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Quest PharmaTech and its competitors.
Is Quest PharmaTech's LT-Debt-to-Total-Asset too high?
Quest PharmaTech's current LT-Debt-to-Total-Asset is 0.00.
How does Quest PharmaTech's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Quest PharmaTech's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Quest PharmaTech and its competitors. Quest PharmaTech's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current LT-Debt-to-Total-Asset is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest PharmaTech Business Description

Other Exchanges QPT:Canada
Address 4342- 97 Street NW, Edmonton, AB, CAN, T6E 5R9
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.